



November 7, 2024

Important Supply Update- Venofer® (iron sucrose injection)

Over the last several months, the US market for intravenous iron experienced an unprecedented increase in demand and in turn, American Regent also realized a significant increase in demand for all its Venofer® (iron sucrose) products.

On the 24th anniversary of the approval of Venofer® (iron sucrose injection) in the United States, American Regent is proud to announce that we are rising to the challenge of meeting the ever-increasing market demand. In fact, this quarter, the company plans to ship an estimated 40% more units than in fourth quarter 2023. American Regent has been and will continue to ship consistently to all major wholesalers on a weekly basis as well as closely monitor ordering patterns.

American Regent has increased production and product availability by:

- Manufacturing Venofer 6-7 days per week, every week
- Increasing inventory holding levels of all key starting materials
- Process improvements enabling reduced filling to release times
- Working to establish improved stock levels in finished goods inventory

We wish to extend sincere thanks to our employees who demonstrated unwavering urgency and diligence, and our partners in trade and in healthcare who did their part to ensure supply continuity. Commitment to product quality, patient safety, and reliable access to our products remains our top priority.

For more information, please contact your American Regent Representative or visit our website www.americanregent.com where we will continue to provide regular supply updates.

NP-VE-US-0101